Please login to the form below

Not currently logged in
Email:
Password:

Amylin

This page shows the latest Amylin news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca and its diabetes plans

AstraZeneca and its diabetes plans

This was then expanded in 2012 when the alliance acquired Amylin, gaining the rights to a portfolio of products for type 2 diabetes, including the long-acting exenatide franchise (Byetta and

Latest news

More from news
Approximately 2 fully matching, plus 56 partially matching documents found.

Latest Intelligence

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    This was then expanded in 2012 when the alliance acquired Amylin, gaining the rights to a portfolio of products for type 2 diabetes, including the exenatide franchise (Byetta and Bydureon).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Adocia names senior members of new US subsidiary Adocia names senior members of new US subsidiary

    Bruce has also held position at Amylin Pharmaceuticals, where he was in charge of Bydureon's phase III studies and safety analysis, a once weekly GLP-1 injectable formulation. ... Daly's experience in the diabetes field also includes several years at

  • Profil Institute appoints former Amylin CEO Profil Institute appoints former Amylin CEO

    Profil Institute appoints former Amylin CEO. Dan Bradbury joins board of diabetes company. ... Bradbury is an experienced figure in the life science industry, serving as CEO of Amylin from 2007 to 2012 until its acquisition by Bristol-Myers Squibb.

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics